In vitro cytotoxic and genotoxic evaluation of peptides used in nuclear medicine (DOTATATE and Ubiquicidin29-41) in CHO-K1 cells

Página do item simplificado
dc.contributor.authorOCAMPO, IVETTE Z.
dc.contributor.authorPASSOS, PRISCILA de Q.S.
dc.contributor.authorCARVALHO, LUMA R. de
dc.contributor.authorCRUZ, CAMILA A.L. da
dc.contributor.authorESTEVES-PEDRO, NATALIA M.
dc.contributor.authorSILVA, FABIANA M. da
dc.contributor.authorHIGA, OLGA Z.
dc.contributor.authorDIAS, LUIZ A.P.
dc.contributor.authorOKAZAKI, KAYO
dc.contributor.authorVIEIRA, DANIEL P.
dc.coverageInternacionalpt_BR
dc.date.accessioned2016-10-07T16:53:57Z
dc.date.available2016-10-07T16:53:57Z
dc.date.issued2016pt_BR
dc.description.abstractMicronucleus (MN) assay constitutes a valuable surrogate to the chromosome aberration technique for in vitro testing of the genotoxicity of substances. As test substances, two peptidic compounds (DOTATATE and Ubiquicidin29-41) used in nuclear medicine, were tested for in vitro cytotoxicity and genotoxicity in CHO-K1 cells. None of the compounds showed detectable cytotoxicity (0.5– 7.3 ng/mL for DOTATATE and 0.3–4.5 ng/mL for UBI29-41), genotoxicity (0.72, 7.2 and 72.0 ng/ml for DOTATATE and 0.45, 4.5 and 45.0 ng/mL for UBI29-41) or cell cycle changes as compared to untreated controls at the concentrations tested. Statistical analysis showed good concordance between two independent analysts. The results corroborate the notion of the safety of the compounds and present improvements of the in vitro MN assay when performed in a pre-clinical trial context that increase the throughput of small-to-medium testing facilities as an alternative to high content screening systems.pt_BR
dc.format.extent1-10pt_BR
dc.identifier.citationOCAMPO, IVETTE Z.; PASSOS, PRISCILA de Q.S.; CARVALHO, LUMA R. de; CRUZ, CAMILA A.L. da; ESTEVES-PEDRO, NATALIA M.; SILVA, FABIANA M. da; HIGA, OLGA Z.; DIAS, LUIZ A.P.; OKAZAKI, KAYO; VIEIRA, DANIEL P. In vitro cytotoxic and genotoxic evaluation of peptides used in nuclear medicine (DOTATATE and Ubiquicidin29-41) in CHO-K1 cells. <b>Cytotechnology</b>, p. 1-10, 2016. DOI: <a href="https://dx.doi.org/10.1007/s10616-016-0024-9">10.1007/s10616-016-0024-9</a>. Disponível em: http://repositorio.ipen.br/handle/123456789/26736.
dc.identifier.doi10.1007/s10616-016-0024-9pt_BR
dc.identifier.issn1573-0778pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-0007-534X
dc.identifier.percentilfi32.69
dc.identifier.urihttp://repositorio.ipen.br/handle/123456789/26736
dc.relation.ispartofCytotechnologypt_BR
dc.rightsopenAccesspt_BR
dc.subjecttoxicity
dc.subjectin vitro
dc.subjectnuclear medicine
dc.subjectpeptides
dc.subjectantimicrobial agents
dc.titleIn vitro cytotoxic and genotoxic evaluation of peptides used in nuclear medicine (DOTATATE and Ubiquicidin29-41) in CHO-K1 cellspt_BR
dc.typeArtigo de periódicopt_BR
dspace.entity.typePublication
ipen.autorIVETTE ZEGARRA OCAMPO
ipen.autorCAMILA AYALA LIRA DA CRUZ
ipen.autorDANIEL PEREZ VIEIRA
ipen.autorKAYO OKAZAKI
ipen.autorLUIS ALBERTO PEREIRA DIAS
ipen.autorOLGA ZAZUCO HIGA
ipen.autorLUMA RAMIREZ DE CARVALHO
ipen.codigoautor10835
ipen.codigoautor12723
ipen.codigoautor3158
ipen.codigoautor1220
ipen.codigoautor796
ipen.codigoautor1023
ipen.codigoautor12133
ipen.contributor.ipenauthorIVETTE ZEGARRA OCAMPO
ipen.contributor.ipenauthorCAMILA AYALA LIRA DA CRUZ
ipen.contributor.ipenauthorDANIEL PEREZ VIEIRA
ipen.contributor.ipenauthorKAYO OKAZAKI
ipen.contributor.ipenauthorLUIS ALBERTO PEREIRA DIAS
ipen.contributor.ipenauthorOLGA ZAZUCO HIGA
ipen.contributor.ipenauthorLUMA RAMIREZ DE CARVALHO
ipen.date.recebimento16-10pt_BR
ipen.identifier.fi1.857pt_BR
ipen.identifier.ipendoc22622pt_BR
ipen.range.fi1.500 - 2.999
ipen.range.percentilfi25.00 - 49.99
ipen.type.genreArtigo
relation.isAuthorOfPublication5c5d765c-9a6d-48c6-a462-649a807d9974
relation.isAuthorOfPublicationb303d804-ff18-47b7-b438-9039d41c01c7
relation.isAuthorOfPublicationc2352608-be9c-4a73-be8c-571f10bb53d2
relation.isAuthorOfPublication131eab71-499a-48c8-8f16-46ffafd0608f
relation.isAuthorOfPublication50b3adab-a651-4225-a05c-ec1b1e37e921
relation.isAuthorOfPublicationeeaeef03-7bd8-4788-ba3d-5c02800475bd
relation.isAuthorOfPublication8e39b9fc-86ca-4b06-bf2a-cb8f163165d8
relation.isAuthorOfPublication.latestForDiscovery5c5d765c-9a6d-48c6-a462-649a807d9974
sigepi.autor.atividadeOCAMPO, IVETTE Z.:10835:810:Spt_BR
sigepi.autor.atividadeCARVALHO, LUMA R. DE:12133:-1:Npt_BR
sigepi.autor.atividadeCRUZ, CAMILA A.L. DA:12723:-1:Npt_BR
sigepi.autor.atividadeHIGA, OLGA Z.:1023:-1:Npt_BR
sigepi.autor.atividadeOKAZAKI, KAYO:1220:-1:Npt_BR
sigepi.autor.atividadeVIEIRA, DANIEL P.:3158:810:Npt_BR
sigepi.autor.atividadeDIAS, LUIZ A.P.:796:110:Npt_BR
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
22622.pdf
Tamanho:
1.62 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar
Coleções
Periódicos